570 related articles for article (PubMed ID: 29703841)
1. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
[TBL] [Abstract][Full Text] [Related]
2. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.
Iwata TN; Sugihara K; Wada T; Agatsuma T
PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081
[TBL] [Abstract][Full Text] [Related]
3. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
[TBL] [Abstract][Full Text] [Related]
4. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J
Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116
[TBL] [Abstract][Full Text] [Related]
5. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys.
Nagai Y; Oitate M; Shiozawa H; Ando O
Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.
Mauricio D; Bellone S; Mutlu L; McNamara B; Manavella DD; Demirkiran C; Verzosa MSZ; Buza N; Hui P; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Mar; 170():38-45. PubMed ID: 36610380
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.
Andrikopoulou A; Zografos E; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Clin Breast Cancer; 2021 Jun; 21(3):e212-e219. PubMed ID: 32917537
[TBL] [Abstract][Full Text] [Related]
9. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Takegawa N; Tsurutani J; Kawakami H; Yonesaka K; Kato R; Haratani K; Hayashi H; Takeda M; Nonagase Y; Maenishi O; Nakagawa K
Int J Cancer; 2019 Dec; 145(12):3414-3424. PubMed ID: 31087550
[TBL] [Abstract][Full Text] [Related]
10. [Development of New ADC Technology with Topoisomerase I Inhibitor].
Agatsuma T
Yakugaku Zasshi; 2017; 137(5):545-550. PubMed ID: 28458286
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
12. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S
J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843
[TBL] [Abstract][Full Text] [Related]
13. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K
Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938
[TBL] [Abstract][Full Text] [Related]
14. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
15. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
16. Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Suzuki M; Yagishita S; Sugihara K; Ogitani Y; Nishikawa T; Ohuchi M; Teishikata T; Jikoh T; Yatabe Y; Yonemori K; Tamura K; Hasegawa K; Hamada A
Clin Cancer Res; 2021 Jul; 27(14):3970-3979. PubMed ID: 33980613
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T
Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
Xu H; Zhang H; Guo W; Zhong X; Sun J; Zhang T; Wang Z; Ma X
BMC Cancer; 2022 Aug; 22(1):923. PubMed ID: 36028823
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice.
Okamoto H; Oitate M; Hagihara K; Shiozawa H; Furuta Y; Ogitani Y; Kuga H
Xenobiotica; 2020 Oct; 50(10):1242-1250. PubMed ID: 32306807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]